“Right-to-Try” experimental drugs: an overview

The “Right-to-Try” experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early access to experimental drugs for the treatment of life-threatening diseases and a potential boon to many young and under-capitalized biotechnology or pharmaceutical companies. The pros and cons...

Descripción completa

Detalles Bibliográficos
Autor principal: Mahant, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309195/
https://www.ncbi.nlm.nih.gov/pubmed/32576276
http://dx.doi.org/10.1186/s12967-020-02427-4
_version_ 1783549165298515968
author Mahant, Vijay
author_facet Mahant, Vijay
author_sort Mahant, Vijay
collection PubMed
description The “Right-to-Try” experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early access to experimental drugs for the treatment of life-threatening diseases and a potential boon to many young and under-capitalized biotechnology or pharmaceutical companies. The pros and cons of experimental drugs, including a number of “cutting edge” scientific, clinical, and a number of synergistic approaches such as artificial intelligence, machine learning, big data, data refineries, electronic health records, data driven clinical decisions and risk mitigation are reviewed.
format Online
Article
Text
id pubmed-7309195
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73091952020-06-23 “Right-to-Try” experimental drugs: an overview Mahant, Vijay J Transl Med Review The “Right-to-Try” experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early access to experimental drugs for the treatment of life-threatening diseases and a potential boon to many young and under-capitalized biotechnology or pharmaceutical companies. The pros and cons of experimental drugs, including a number of “cutting edge” scientific, clinical, and a number of synergistic approaches such as artificial intelligence, machine learning, big data, data refineries, electronic health records, data driven clinical decisions and risk mitigation are reviewed. BioMed Central 2020-06-23 /pmc/articles/PMC7309195/ /pubmed/32576276 http://dx.doi.org/10.1186/s12967-020-02427-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Mahant, Vijay
“Right-to-Try” experimental drugs: an overview
title “Right-to-Try” experimental drugs: an overview
title_full “Right-to-Try” experimental drugs: an overview
title_fullStr “Right-to-Try” experimental drugs: an overview
title_full_unstemmed “Right-to-Try” experimental drugs: an overview
title_short “Right-to-Try” experimental drugs: an overview
title_sort “right-to-try” experimental drugs: an overview
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309195/
https://www.ncbi.nlm.nih.gov/pubmed/32576276
http://dx.doi.org/10.1186/s12967-020-02427-4
work_keys_str_mv AT mahantvijay righttotryexperimentaldrugsanoverview

Ejemplares similares